Man Group plc reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 34.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 90,974 shares of the medical research company's stock after selling 48,777 shares during the period. Man Group plc owned about 0.05% of IQVIA worth $17,877,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IQV. Vanguard Group Inc. raised its stake in shares of IQVIA by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock worth $3,956,087,000 after buying an additional 105,504 shares during the last quarter. Canada Pension Plan Investment Board boosted its holdings in IQVIA by 20.0% during the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock worth $841,461,000 after purchasing an additional 712,958 shares during the last quarter. Geode Capital Management LLC raised its position in IQVIA by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock worth $818,315,000 after acquiring an additional 77,981 shares in the last quarter. Invesco Ltd. raised its position in IQVIA by 53.4% during the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after acquiring an additional 902,226 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its position in IQVIA by 2.5% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company's stock worth $481,380,000 after acquiring an additional 59,426 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.
IQVIA Price Performance
NYSE:IQV traded up $1.36 during trading hours on Tuesday, hitting $144.90. The stock had a trading volume of 4,613,523 shares, compared to its average volume of 1,536,363. The company has a 50 day simple moving average of $158.99 and a two-hundred day simple moving average of $185.26. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88. The firm has a market capitalization of $25.07 billion, a price-to-earnings ratio of 19.32, a P/E/G ratio of 1.99 and a beta of 1.34.
IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter in the prior year, the firm earned $2.54 earnings per share. The firm's revenue for the quarter was up 2.5% compared to the same quarter last year. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on IQV shares. Citigroup lowered their price target on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. UBS Group lowered their price objective on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. StockNews.com downgraded shares of IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. Mizuho lowered their price objective on IQVIA from $210.00 to $190.00 and set an "outperform" rating on the stock in a research note on Thursday, May 15th. Finally, Barclays decreased their price target on IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Wednesday, May 7th. Eight equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $228.14.
Get Our Latest Analysis on IQVIA
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Recommended Stories
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
